

Pavan Reddy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1083873/publications.pdf>

Version: 2024-02-01

156
papers

12,271
citations

26610

56
h-index

26591

107
g-index

161
all docs

161
docs citations

161
times ranked

11454
citing authors

#	ARTICLE	IF	CITATIONS
1	A redox cycle with complex II prioritizes sulfide quinone oxidoreductase-dependent H ₂ S oxidation. Journal of Biological Chemistry, 2022, 298, 101435.	1.6	28
2	LNCing RNA to immunity. Trends in Immunology, 2022, 43, 478-495.	2.9	12
3	Deletion of bone marrow myeloperoxidase attenuates chronic kidney disease accelerated atherosclerosis. Journal of Biological Chemistry, 2021, 296, 100120.	1.6	5
4	ATG5-Dependent Autophagy Uncouples T-cell Proliferative and Effector Functions and Separates Graft-versus-Host Disease from Graft-versus-Leukemia. Cancer Research, 2021, 81, 1063-1075.	0.4	7
5	ER-to-Golgi transport and SEC23-dependent COPII vesicles regulate T cell alloimmunity. Journal of Clinical Investigation, 2021, 131, .	3.9	6
6	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. Transplantation and Cellular Therapy, 2021, 27, 452-466.	0.6	24
7	RNA-seq of human T cells after hematopoietic stem cell transplantation identifies <i>Linc00402</i> as a regulator of T cell alloimmunity. Science Translational Medicine, 2021, 13, .	5.8	6
8	Type 1 interferon to prevent leukemia relapse after allogeneic transplantation. Blood Advances, 2021, 5, 5047-5056.	2.5	10
9	Mitochondrial complex II in intestinal epithelial cells regulates T cell-mediated immunopathology. Nature Immunology, 2021, 22, 1440-1451.	7.0	22
10	The Absence of NLRP6 in Donor T Cells Exacerbates Gvhd. Blood, 2021, 138, 2766-2766.	0.6	0
11	SEC23A rescues SEC23B-deficient congenital dyserythropoietic anemia type II. Science Advances, 2021, 7, eabj5293.	4.7	4
12	The Endoplasmic Reticulum Cargo Receptor SURF4 Facilitates Efficient Erythropoietin Secretion. Molecular and Cellular Biology, 2020, 40, .	1.1	23
13	Short chain fatty acids: Postbiotics/metabolites and graft versus host disease colitis. Seminars in Hematology, 2020, 57, 1-6.	1.8	24
14	Targeting Signal 3 Extracellularly and Intracellularly in Graft-Versus-Host Disease. Frontiers in Immunology, 2020, 11, 722.	2.2	6
15	Prevention and Treatment of Acute Graft-versus-Host Disease in Children, Adolescents, and Young Adults. Biology of Blood and Marrow Transplantation, 2020, 26, e101-e112.	2.0	30
16	MicroRNA-142 Is Critical for the Homeostasis and Function of Type 1 Innate Lymphoid Cells. Immunity, 2019, 51, 479-490.e6.	6.6	39
17	SNARE protein SEC22B regulates early embryonic development. Scientific Reports, 2019, 9, 11434.	1.6	7
18	Intracellular Sensors and Cellular Metabolism in Allogeneic Hematopoietic Stem Cell Transplantation. , 2019, , 349-374.		0

#	ARTICLE	IF	CITATIONS
19	Host NLRP6 exacerbates graft-versus-host disease independent of gut microbial composition. <i>Nature Microbiology</i> , 2019, 4, 800-812.	5.9	36
20	A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1492-1497.	2.0	23
21	A Pipeline for Faecal Host DNA Analysis by Absolute Quantification of LINE-1 and Mitochondrial Genomic Elements Using ddPCR. <i>Scientific Reports</i> , 2019, 9, 5599.	1.6	9
22	Assessment of Individual versus Composite Endpoints of Acute Graft-versus-Host Disease in Determining Long-Term Survival after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1682-1688.	2.0	5
23	Maintenance sorafenib in FLT3-ITD AML following allogeneic HCT favorably impacts relapse and overall survival. <i>Bone Marrow Transplantation</i> , 2019, 54, 1518-1520.	1.3	18
24	The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. <i>Blood Advances</i> , 2019, 3, 4034-4042.	2.5	63
25	Computational analysis of continuous body temperature provides early discrimination of graft-versus-host disease in mice. <i>Blood Advances</i> , 2019, 3, 3977-3981.	2.5	5
26	Cognitive Function and Quality of Life in Vorinostat-Treated Patients after Matched Unrelated Donor Myeloablative Conditioning Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 343-353.	2.0	12
27	miR-142 controls metabolic reprogramming that regulates dendritic cell activation. <i>Journal of Clinical Investigation</i> , 2019, 129, 2029-2042.	3.9	41
28	Mitochondrial Complex II in Intestinal Epithelial Cells Is a Critical Metabolic Checkpoint That Regulates Severity of Gastrointestinal Graft-Versus-Host Disease. <i>Blood</i> , 2019, 134, 584-584.	0.6	1
29	Rational Modification of Intestinal Microbiome and Metabolites after Allogeneic Hematopoietic Stem Cell Transplantation with Resistant Starch: A Pilot Study. <i>Blood</i> , 2019, 134, 3276-3276.	0.6	1
30	NLRP6 in Donor T Cells Separately Regulates CD4 and CD8 Mediated Graft-Versus-Host Disease in Experimental Murine BMT. <i>Blood</i> , 2019, 134, 1926-1926.	0.6	0
31	The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease. <i>Blood</i> , 2019, 134, 367-367.	0.6	0
32	The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1322-1340.	2.0	85
33	Î±1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. <i>Blood</i> , 2018, 131, 1372-1379.	0.6	81
34	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. <i>Nature Medicine</i> , 2018, 24, 282-291.	15.2	216
35	MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. <i>Blood</i> , 2018, 131, 2846-2855.	0.6	140
36	Microbial metabolites and graft versus host disease. <i>American Journal of Transplantation</i> , 2018, 18, 23-29.	2.6	40

#	ARTICLE	IF	CITATIONS
37	Graft-Versus-Host Disease and Graft-Versus-Leukemia Responses. , 2018, , 1650-1668.e10.		1
38	Editorial: Non-coding RNAs and Graft versus Host Disease. <i>Frontiers in Immunology</i> , 2018, 9, 2713.	2.2	2
39	SAG/RBX2 E3 Ubiquitin Ligase Differentially Regulates Inflammatory Responses of Myeloid Cell Subsets. <i>Frontiers in Immunology</i> , 2018, 9, 2882.	2.2	11
40	Microbes and Their Metabolites Correlate with Hematopoietic Stem Cell Transplantation Outcomes?. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, e7-e8.	2.0	1
41	Mitochondrial Deacetylase SIRT3 Plays an Important Role in Donor T Cell Responses after Experimental Allogeneic Hematopoietic Transplantation. <i>Journal of Immunology</i> , 2018, 201, 3443-3455.	0.4	22
42	Murine Models of Steroid Refractory Graft-versus-Host Disease. <i>Scientific Reports</i> , 2018, 8, 12475.	1.6	13
43	Microbial metabolite sensor GPR43 controls severity of experimental GVHD. <i>Nature Communications</i> , 2018, 9, 3674.	5.8	102
44	Non-Coding RNA Mediated Regulation of Allogeneic T Cell Responses After Hematopoietic Transplantation. <i>Frontiers in Immunology</i> , 2018, 9, 1110.	2.2	12
45	Survival signal REG3 β prevents crypt apoptosis to control acute gastrointestinal graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2018, 128, 4970-4979.	3.9	94
46	Tissue tolerance: a distinct concept to control acute GVHD severity. <i>Blood</i> , 2017, 129, 1747-1752.	0.6	56
47	GVHD: ferocity affects feracitas. <i>Blood</i> , 2017, 129, 1068-1069.	0.6	0
48	Regulating Damage from Sterile Inflammation: A Tale of Two Tolerances. <i>Trends in Immunology</i> , 2017, 38, 231-235.	2.9	10
49	Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT. <i>Blood</i> , 2017, 130, 1760-1767.	0.6	57
50	STAT3 Expression in Host Myeloid Cells Controls Graft-versus-Host Disease Severity. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1622-1630.	2.0	7
51	A Critical Analysis of the Role of SNARE Protein SEC22B in Antigen Cross-Presentation. <i>Cell Reports</i> , 2017, 19, 2645-2656.	2.9	42
52	Genome-Wide STAT3 Binding Analysis after Histone Deacetylase Inhibition Reveals Novel Target Genes in Dendritic Cells. <i>Journal of Innate Immunity</i> , 2017, 9, 126-144.	1.8	8
53	An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. <i>JCI Insight</i> , 2017, 2, e89798.	2.3	166
54	IAPs protect host target tissues from graft-versus-host disease in mice. <i>Blood Advances</i> , 2017, 1, 1517-1532.	2.5	15

#	ARTICLE	IF	CITATIONS
55	Siglec-G represses DAMP-mediated effects on T cells. JCI Insight, 2017, 2, .	2.3	37
56	Fibroblastic niches prime T cell alloimmunity through Delta-like Notch ligands. Journal of Clinical Investigation, 2017, 127, 1574-1588.	3.9	72
57	Altered homeostatic regulation of innate and adaptive immunity in lower gastrointestinal tract GVHD pathogenesis. Journal of Clinical Investigation, 2017, 127, 2441-2451.	3.9	37
58	Danger Signals and Graft-versus-host Disease: Current Understanding and Future Perspectives. Frontiers in Immunology, 2016, 7, 539.	2.2	85
59	Advances in understanding the pathogenesis of graft-versus-host disease. British Journal of Haematology, 2016, 173, 190-205.	1.2	67
60	SAG/Rbx2-Dependent Neddylation Regulates T-Cell Responses. American Journal of Pathology, 2016, 186, 2679-2691.	1.9	25
61	Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial. Biology of Blood and Marrow Transplantation, 2016, 22, 862-868.	2.0	40
62	Cut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nature Immunology, 2016, 17, 505-513.	7.0	536
63	Reprint of: Acute Graft-versus-Host Disease: Novel Biological Insights. Biology of Blood and Marrow Transplantation, 2016, 22, S3-S8.	2.0	13
64	Acute Graft-versus-Host Disease: Novel Biological Insights. Biology of Blood and Marrow Transplantation, 2016, 22, 11-16.	2.0	92
65	Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series. Biology of Blood and Marrow Transplantation, 2016, 22, 54-60.	2.0	12
66	FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML. Bone Marrow Transplantation, 2016, 51, 511-520.	1.3	40
67	Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans. Blood, 2015, 125, 815-819.	0.6	95
68	Lung parenchyma-derived IL-6 promotes IL-17A-dependent acute lung injury after allogeneic stem cell transplantation. Blood, 2015, 125, 2435-2444.	0.6	73
69	Mature T cell responses are controlled by microRNA-142. Journal of Clinical Investigation, 2015, 125, 2825-2840.	3.9	81
70	Host CD8 ⁺ Dendritic Cells May Be a Key Factor for Separating Graft-versus-Host Disease from Graft-versus-Leukemia. Biology of Blood and Marrow Transplantation, 2015, 21, 775-776.	2.0	6
71	BET bromodomain inhibition suppresses graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood, 2015, 125, 2724-2728.	0.6	41
72	The Microbiome and Graft Versus Host Disease. Current Stem Cell Reports, 2015, 1, 39-47.	0.7	14

#	ARTICLE	IF	CITATIONS
73	Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation. <i>Onc Immunology</i> , 2015, 4, e1016699.	2.1	8
74	Donor T Cells Intrinsic Responses to Damps Regulated By Siglec-G-CD24 Axis Mitigate Gvhd but Maintain GVL in Experimental BMT Model. <i>Blood</i> , 2015, 126, 229-229.	0.6	1
75	Genome-Wide Binding Studies of Acetyl-STAT3 Demonstrates a Novel Regulatory Pathway in Dendritic Cells. <i>Blood</i> , 2015, 126, 647-647.	0.6	0
76	The Role of Dendritic Cells in Graft-Versus-Tumor Effect. <i>Frontiers in Immunology</i> , 2014, 5, 66.	2.2	14
77	The Difficulty in Diagnosing Cord Colitis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 906-907.	2.0	3
78	Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 87-95.	5.1	113
79	Participation in Clinical Research: Perspectives of Adult Patients and Parents of Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1604-1611.	2.0	30
80	Current and emerging strategies for the prevention of graft-versus-host disease. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 536-547.	12.5	180
81	Etanercept plus Topical Corticosteroids as Initial Therapy for Grade One Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1426-1434.	2.0	20
82	Engraftment Syndrome after Allogeneic Hematopoietic Cell Transplantation Predicts Poor Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1407-1417.	2.0	80
83	Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice. <i>Blood</i> , 2014, 123, 3512-3523.	0.6	76
84	ST2 as a Marker for Risk of Therapy-Resistant Graft-versus-Host Disease and Death. <i>New England Journal of Medicine</i> , 2013, 369, 529-539.	13.9	339
85	Mouse Models in Bone Marrow Transplantation and Adoptive Cellular Therapy. <i>Seminars in Hematology</i> , 2013, 50, 131-144.	1.8	10
86	The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease. <i>Blood</i> , 2013, 122, 4119-4128.	0.6	54
87	Biology of Graft-versus-Host Responses: Recent Insights. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S10-S14.	2.0	47
88	Influence of Donor Microbiota on the Severity of Experimental Graft-versus-Host-Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 164-168.	2.0	29
89	Intracellular sensors of immunity and allogeneic hematopoietic stem cell transplantation. , 2013, , 425-447.		6
90	Host-derived CD8+ dendritic cells are required for induction of optimal graft-versus-tumor responses after experimental allogeneic bone marrow transplantation. <i>Blood</i> , 2013, 121, 4231-4241.	0.6	34

#	ARTICLE	IF	CITATIONS
91	Neddylation plays an important role in the regulation of murine and human dendritic cell function. Blood, 2013, 122, 2062-2073.	0.6	66
92	Allogeneic T cell responses are regulated by a specific miRNA-mRNA network. Journal of Clinical Investigation, 2013, 123, 4739-4754.	3.9	36
93	Targeting deacetylases to improve outcomes after allogeneic bone marrow transplantation. Transactions of the American Clinical and Climatological Association, 2013, 124, 152-62.	0.9	2
94	Donor- but not host-derived interleukin-10 contributes to the regulation of experimental graft-versus-host disease. Journal of Leukocyte Biology, 2012, 91, 667-675.	1.5	29
95	Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 564-569.	3.3	125
96	Editorial: HDAC inhibition begets more MDSCs. Journal of Leukocyte Biology, 2012, 91, 679-681.	1.5	5
97	Tolerance without toxicity? α 1-antitrypsin as a novel alternative to immunosuppression. Expert Review of Clinical Immunology, 2012, 8, 397-399.	1.3	9
98	Role of Cytokines in the Pathophysiology of Acute Graft-Versus-Host Disease (GVHD)â€“ Are Serum/Plasma Cytokines Potential Biomarkers for Diagnosis of Acute GVHD Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)? Current Stem Cell Research and Therapy, 2012, 7, 229-239.	0.6	37
99	Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoieticâ€“derived antigen-presenting cells. Blood, 2012, 119, 3844-3853.	0.6	86
100	Emerging Therapies in Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, S125-S131.	2.0	7
101	GVHD Prevention: An Ounce Is Better Than a Pound. Biology of Blood and Marrow Transplantation, 2012, 18, S17-S26.	2.0	10
102	Cellular Therapy for Hematology Malignancies: Allogeneic Hematopoietic Stem Transplantation, Graft-Versus-Host Disease, and Graft Versus Leukemia Effects. , 2012, , 303-366.		1
103	Host Basophils Are Dispensable for Induction of Donor T Helper 2 Cell Differentiation and Severity of Experimental Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2011, 17, 1747-1753.	2.0	8
104	HDAC Inhibition and Graft Versus Host Disease. Molecular Medicine, 2011, 17, 404-416.	1.9	71
105	Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood, 2011, 118, 6702-6708.	0.6	277
106	Ikars-Notch axis in host hematopoietic cells regulates experimental graft-versus-host disease. Blood, 2011, 118, 192-204.	0.6	94
107	Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality. Blood, 2011, 117, 6172-6183.	0.6	132
108	Donor Tregs suppress the good with the bad after allogeneic BMT. Leukemia Research, 2011, 35, 1541-1542.	0.4	1

#	ARTICLE	IF	CITATIONS
109	Manipulating the Bioenergetics of Alloreactive T Cells Causes Their Selective Apoptosis and Arrests Graft-Versus-Host Disease. <i>Science Translational Medicine</i> , 2011, 3, 67ra8.	5.8	153
110	Interleukin-6 Modulates Graft-versus-Host Responses after Experimental Allogeneic Bone Marrow Transplantation. <i>Clinical Cancer Research</i> , 2011, 17, 77-88.	3.2	155
111	Immunization with host-type CD8 α^+ dendritic cells reduces experimental acute GVHD in an IL-10 α -dependent manner. <i>Blood</i> , 2010, 115, 724-735.	0.6	26
112	A Crucial Role for Host APCs in the Induction of Donor CD4 $^+$ CD25 $^+$ Regulatory T Cell-Mediated Suppression of Experimental Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2010, 185, 3866-3872.	0.4	47
113	Emerging drugs for acute graft-versus-host disease. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 219-232.	1.0	5
114	Cutting Edge: Negative Regulation of Dendritic Cells through Acetylation of the Nonhistone Protein STAT-3. <i>Journal of Immunology</i> , 2009, 182, 5899-5903.	0.4	129
115	Graft-versus-host disease. <i>Lancet</i> , The, 2009, 373, 1550-1561.	6.3	2,093
116	A biomarker panel for acute graft-versus-host disease. <i>Blood</i> , 2009, 113, 273-278.	0.6	348
117	Combined Th2 cytokine deficiency in donor T cells aggravates experimental acute graft-vs-host disease. <i>Experimental Hematology</i> , 2008, 36, 988-996.	0.2	56
118	Differential susceptibility of C57BL/6NCr and B6.Cg-Ptprca mice to commensal bacteria after whole body irradiation in translational bone marrow transplant studies. <i>Journal of Translational Medicine</i> , 2008, 6, 10.	1.8	20
119	GVHD pathophysiology: is acute different from chronic?. <i>Best Practice and Research in Clinical Haematology</i> , 2008, 21, 101-117.	0.7	71
120	Mouse Models of Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 129-135.	2.0	98
121	Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. <i>Blood</i> , 2008, 111, 2470-2475.	0.6	183
122	Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. <i>Blood</i> , 2008, 112, 1515-1521.	0.6	198
123	Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase α -dependent DC functions and regulates experimental graft-versus-host disease in mice. <i>Journal of Clinical Investigation</i> , 2008, 118, 2562-73.	3.9	243
124	Pathophysiology of Acute Graft-versus-Host Disease. , 2008, , 563-588.		1
125	Histone Deacetylase Inhibitors: Novel Immunomodulators. <i>Current Enzyme Inhibition</i> , 2007, 3, 207-215.	0.3	2
126	A Novel Role for the Semaphorin Sema4D in the Induction of Allo-responses. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1294.e1-1294.e11.	2.0	16

#	ARTICLE	IF	CITATIONS
127	Pathophysiology of acute graft-versus-host disease: recent advances. Translational Research, 2007, 150, 197-214.	2.2	110
128	Blocking HDACs boosts regulatory T cells. Nature Medicine, 2007, 13, 1282-1284.	15.2	17
129	Lymphopenia-induced proliferation of donor T cells reduces their capacity for causing acute graft-versus-host disease. Experimental Hematology, 2007, 35, 274-286.	0.2	23
130	Benzodiazepine-423, an Inhibitor of Mitochondrial Respiration, Causes Selective Apoptosis of Activated Lymphocytes and Reverses Experimental GVHD While Preserving GVL Effects.. Blood, 2007, 110, 68-68.	0.6	4
131	Etanercept Plus Methylprednisolone as Initial Therapy for Acute GVHD.. Blood, 2007, 110, 39-39.	0.6	0
132	Pathophysiology of Graft-Versus-Host Disease. Seminars in Hematology, 2006, 43, 3-10.	1.8	358
133	Nephrotic syndrome associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2006, 38, 351-357.	1.3	84
134	Critical role of host $\gamma\delta$ T cells in experimental acute graft-versus-host disease. Blood, 2005, 106, 749-755.	0.6	67
135	A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nature Medicine, 2005, 11, 1244-1249.	15.2	223
136	Histone Deacetylase Inhibitors Induce Immuno-Dominant Suppression of Dendritic Cells.. Blood, 2005, 106, 456-456.	0.6	1
137	Extracorporeal photo-chemotherapy for graft-versus-host disease. Haematologica, 2005, 90, 1013B.	1.7	0
138	Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3921-3926.	3.3	278
139	Host Dendritic Cells Alone Are Sufficient to Initiate Acute Graft-versus-Host Disease. Journal of Immunology, 2004, 172, 7393-7398.	0.4	225
140	Interleukin-18: recent advances. Current Opinion in Hematology, 2004, 11, 405-410.	1.2	129
141	Allo-Antigen Expression on Both APCs and Tumor Is Required To Elicit an Effective GVL Response after Experimental Allogeneic BMT.. Blood, 2004, 104, 595-595.	0.6	1
142	Host $\gamma\delta$ T cells Exacerbate Experimental Acute Graft-Versus-Host Disease through Activation of Host Antigen Presenting Cells.. Blood, 2004, 104, 3045-3045.	0.6	0
143	Role of CXCR3-induced donor T-cell migration in acute GVHD. Experimental Hematology, 2003, 31, 897-902.	0.2	152
144	Role of interleukin-18 in acute graft-vs-host disease. Translational Research, 2003, 141, 365-371.	2.4	37

#	ARTICLE	IF	CITATIONS
145	Pathophysiology of acute graft-versus-host disease. Hematological Oncology, 2003, 21, 149-161.	0.8	145
146	Immunobiology of acute graft-versus-host disease. Blood Reviews, 2003, 17, 187-194.	2.8	234
147	Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biology of Blood and Marrow Transplantation, 2003, 9, 505-511.	2.0	204
148	Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood, 2003, 101, 2877-2885.	0.6	65
149	Early changes in gene expression profiles of hepatic GVHD uncovered by oligonucleotide microarrays. Blood, 2003, 102, 763-771.	0.6	74
150	Impaired thymic negative selection causes autoimmune graft-versus-host disease. Blood, 2003, 102, 429-435.	0.6	97
151	Flt3 ligand therapy for recipients of allogeneic bone marrow transplants expands host CD8 ⁺ dendritic cells and reduces experimental acute graft-versus-host disease. Blood, 2002, 99, 1825-1832.	0.6	72
152	Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation. Blood, 2002, 100, 3429-3431.	0.6	37
153	Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nature Medicine, 2002, 8, 575-581.	15.2	495
154	Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versus-host disease. Journal of Clinical Investigation, 2002, 109, 1249-1256.	3.9	76
155	Interleukin-18 Regulates Acute Graft-Versus-Host Disease by Enhancing Fas-mediated Donor T Cell Apoptosis. Journal of Experimental Medicine, 2001, 194, 1433-1440.	4.2	161
156	Pathobiology of graft-versus-host disease. , 0, , 297-310.		0